Licogliflozin

Chemical compound

Investigational

Identifiers

IUPAC name

(2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

CAS Number

1291094-73-9

PubChem CID

52913524

Chemical and physical dataFormulaC₂₃H₂₈O₇Molar mass416.470 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

CCC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4

InChI

InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1
Key:XFJAMQQAAMJFGB-ZQGJOIPISA-N

Licogliflozin is a drug which acts as an SGLT2 inhibitor. It was originally developed as a potential treatment for obesity,^[1] but has also been investigated for other applications such as treating symptoms of polycystic ovary syndrome and nonalcoholic steatohepatitis.^[2]^[3]

References

^ Zaki AM, Abo-Elnour DE, Abdalla YE, Hassan RY, Salama MK, Elboraay T, et al. (November 2022). "Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials". Diabetes & Metabolic Syndrome. 16 (11): 102657. doi:10.1016/j.dsx.2022.102657. PMID 36335885.
^ Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D, et al. (November 2021). "Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial". Diabetes, Obesity & Metabolism. 23 (11): 2595–2599. doi:10.1111/dom.14495. PMID 34263971.
^ Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, et al. (July 2022). "Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study". Nature Medicine. 28 (7): 1432–1438. doi:10.1038/s41591-022-01861-9. PMC 10061496. PMID 35725922.